DOCSLIB.ORG

Plan Ahead For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE AMERICAN ASSOCIATION OF AAI IMMUNOLOGISTS NEWSLETTER DECEMBER 2016 Plan Ahead for Great science awaits you in Washington, D.C., Page 25 How will the new White House look at science? Page 4 ... Success at the Summer Immunology Courses, Page 18 COMING SOON An open access, fully peer-reviewed journal published by The American Association of Immunologists, Inc. Editors-in-Chief Leslie J. Berg and Michael S. Krangel University of Massachusetts Duke University Medical School Medical Center The pace of progress in the fi eld of immunology - in both basic research and successful therapies - is advancing as never before. ImmunoHorizons will contribute to this progress by • Reducing the time needed to submit a manuscript • Publishing research work using an open access model ImmunoHorizons is a fully peer-reviewed journal committed to advancing the knowledge of immunology. All decisions are made by editors who are practicing scientists. More at www.aai.org/ImmunoHorizons COMING SOON IN THIS ISSUE An open access, fully peer-reviewed journal published by The American Association of Immunologists, Inc. The American Association Departments of Immunologists 4 Public Affairs 1451 Rockville Pike, Suite 650 Rockville, MD 20852 10 Members in the News Tel: 301-634-7178 Suzanne Topalian, Jedd Wolchok Fax: 301-634-7887 Receive Taubman Prize E-mail: [email protected] Tasuku Honjo Wins Kyoto Prize www.aai.org 18 Report from AAI Summer Editors-in-Chief Alberto Mantovani, Michel Nussenzweig Immunology Courses Member Services Receive Koch Award Tel: 301-634-7195 Dan Littman, Ton Schumacher, John Wherry E-mail: [email protected] Leslie J. Berg and Michael S. Krangel Receive CRI Awards University of Massachusetts Duke University The Journal Medical School Medical Center of Immunology 16 In Memoriam Tel: 301-634-7197 Henry N. Claman E-mail: [email protected] 18 Education The pace of progress in the fi eld of immunology - in both basic www.jimmunol.org research and successful therapies - is advancing as never before. 20 Outreach Update Council 20 Outreach Update ImmunoHorizons will contribute to this progress by 38 Grants and Awards • Reducing the time needed to submit a manuscript President 39 Meetings and Events • Publishing research work using an open access model Arlene H. Sharpe, M.D., Ph.D. Vice President Features Wayne M. Yokoyama, M.D. ImmunoHorizons is a fully peer-reviewed journal committed 27 Plan Ahead: IMMUNOLOGY 2017™ to advancing the knowledge of immunology. All decisions are Past President Dan R. Littman, M.D., Ph.D. 30 Meet Your AAI Committees 2016-2017 made by editors who are practicing scientists. Secretary-Treasurer 36 NIH Workshop Commemorates Mike Potter Edith M. Lord, Ph.D. 27 Plan Ahead for More at www.aai.org/ImmunoHorizons IMMUNOLOGY 2017™ Councillors JoAnne L. Flynn, Ph.D. Jeremy M. Boss, Ph.D. Jenny P. Ting, Ph.D. Gary A. Koretzky, M.D., Ph.D. Executive Director Connect with AAI! M. Michele Hogan, Ph.D. Have a story idea for a future issue of the AAI Newsletter? Send us an email! Interested in staying up with the www.aai.org/ latest on AAI? Keep in touch through our social media channels. Follow us on Twitter, “Like” us on Facebook, About/Departments-Staff and keep abreast of daily developments in the world of immunology. @ImmunologyAAI @J_Immunol (The Journal of Immunology) © The American Association of Immunologists, Inc. @ImmunologyAAI [email protected] (story ideas and comments about the AAI Newsletter) www.aai.org AAI NEWSLETTER 3 PUBLIC AFFAIRS Republicans Take the White House, of a comprehensive vaccination program. We have been Maintain Both Chambers of Congress successful with other public service programs and this seems to be of enough importance that we should put resources An Initial Look at President-Elect Trump’s Views on Science against this task.” He also acknowledged that “scientific advances do require long term investment” and that “we On January 20, 2017, Donald J. Trump will be sworn in must have programs such as a visible space program and as the 45th President of the United States. In many ways, institutional research that serve as incubators to innovation however, the job has already begun. The Trump campaign, and the advancement of science and engineering in a which has had a transition team in place for months, has number of fields.” grown considerably larger since the election and is helping the president-elect make nearly 4,000 appointments, more The 2016 elections did not dramatically change the than 1,000 of which will require Senate confirmation. makeup of Congress. Republicans still control both the Senate and the House, although Democrats did narrow the Some of those appointments are critical to the Republican majorities. The Democrats gained two seats in biomedical research community, including the Secretary the Senate, bringing the current composition of the Senate of Health and Human Services, the Director of the National to 52 Republicans and 48 Institutes of Health (NIH), Democrats (including two and the Director of the independents who caucus National Cancer Institute. Two particularly strong NIH champions, with the Democrats). In the The selection of these Senators Roy Blunt (R-MO) and Patty Murray House, Democrats picked up appointments can take a six seats, but the Republican great deal of time: President (D-WA), were re-elected to the Senate. majority remains quite large Obama nominated Francis at 241–194. Collins, M.D., Ph.D., as director of NIH more than six months into his presidency, Two particularly strong NIH champions, Senators and it took another month for the Senate to confirm his Roy Blunt (R-MO) and Patty Murray (D-WA), were re- nomination. However, Trump has already nominated Rep. elected to the Senate. Murray was subsequently elected as Tom Price (R-GA, 6th), chair of the House Budget Committee, assistant Democratic Leader, making her the third-highest to be Secretary of Health and Human Services. Price, an ranking Democrat in the Senate. She will also continue orthopedist and strong fiscal conservative who has expressed to serve as ranking member of the Senate Committee on opposition to the National Cancer Moonshot and embryonic Health, Education, Labor, and Pensions, which authorizes stem cell research, drafted legislation to repeal and replace programs and activities at NIH. The seat of long-time NIH the Affordable Care Act (Obamacare). Senate confirmation champion and 2015 AAI Public Service Awardee Senator hearings on the nomination have not yet been scheduled. Barbara Mikulski (D-MD), who is retiring at the end of the year, was won by another leading NIH advocate, President-Elect Trump said little about science during Representative Chris Van Hollen (D-MD, 8th), winner of his campaign. Some of what he did say has drawn harsh the 2011 AAI Public Service Award, who represents the criticism from the scientific community. For example, he district that includes NIH, the American Association of has claimed that vaccines can cause autism and that global Immunologists (AAI), and the Federation of American warming is a hoax invented by China. In addition, on a 2015 Societies for Experimental Biology (FASEB). radio program, Trump said that much of what he has heard about NIH is “terrible” (see http://bit.ly/2eMa5PC). However, FASEB, of which AAI is a founding member, held a in response to key questions about science, selected by webinar on November 16th to talk about the election ScienceDebate.org, he provided some responses that, if results and discuss what is next for research funding. implemented by his administration, would be received The archived webinar is now available on the FASEB quite favorably by the scientific community. For example, website at www.faseb.org. he said that “we should educate the public on the values 4 AAI NEWSLETTER DECEMBER 2016 Federal Government Remains Flat-Funded Under AAI Participates in Rally for Medical Short-Term Spending Deal Research Hill Day Includes $352 Million in New Funding for NIH AAI was pleased to cosponsor the 2016 Rally for Medical Research Hill Day, which took place on September 22. Earlier this month, Congress passed, and President Representing AAI and visiting the Maine, New Hampshire, Obama signed into law, a Continuing Resolution (CR) that and Idaho delegations were AAI Committee on Public Affairs funds most federal agencies and programs at roughly last (CPA) member and former AAI Public Policy Fellow Ling year’s levels through April 28, 2017. Most notably, the law Cao, M.D., Ph.D. (AAI ’08) and AAI Director of Public Policy provides NIH with an additional $352 million for the 21st and Government Affairs Lauren Gross, J.D. CPA member Century Cures Act (see “Bipartisan Medical Research Bill David Chaplin, M.D., Ph.D. (AAI ’86); former AAI Public Becomes Law” on page 6). Policy Fellow Jennifer Lori Blanchfield, Ph.D. (AAI ’07); and Although fiscal year (FY) 2017 began on October AAI members Achsah Keegan, Ph.D. (AAI ’90) and Manoj K. 1, Congress had failed to pass any of its annual Mishra, Ph.D. (AAI ’03) also participated in the Rally Hill Day. appropriations bills before that date. As a result, it Nearly 350 scientists, patient advocates, and others passed a CR that funded most of the government, from 37 states and the District of Columbia participated including NIH, at approximately last year’s funding levels in meetings at more than 250 House and Senate offices. through December 9. AAI and many other groups in the The goal of the event, which took place as Congress biomedical research community had urged Congress continued preparing appropriations bills for FY 2017, was to complete its FY 2017 appropriations bills before the to advocate for robust, sustained, and predictable funding first CR expired: in its November 16 letter to House and increases for NIH.
Recommended publications
  • The 49Th Annual Meeting of the Japanese Society for Immunology

    The 49Th Annual Meeting of the Japanese Society for Immunology

    http://icongroup.co.jp/49immunology/ The 49th Annual Meeting of the Japanese Society for Immunology December 8, 2020－Online Meeting P r e s i d e n t： Hiroshi Kiyono, President and Chairman of Board, JSI COVID-19 and Immunity Keynote Remarks Registration Anthony S. Fauci, Director of NIAID, U.S.A. http://icongroup.co.jp/49immunology/ November 2 (Noon - JST) Symposium Early －November 30 (Noon - JST) Vaccine and Immunity * Credit card or Bank transfer December 1 (Noon - JST) Akiko Iwasaki, Yale University, U.S.A. Late －December 25 (Noon - JST) Alessandro Sette, La Jolla Institute for Immunology, U.S.A. * Credit card only George Fu Gao, China CDC, China Regular Member: 1,000JPY, Student Member: Free Hironori Nakagami, Osaka University, Japan Non-member: 2,000JPY, Student Non-member: 500JPY Ken J Ishii, The University Tokyo, Japan Cytokine Storm and Related Disease ■Steering committee & Program Committee Tadamitsu Kishimoto, Osaka University, Japan Chair: Toshiaki Ohteki, Tokyo Medical and Dental University Josef Penninger, University of British Columbia, Canada Members: Miyuki Azuma, Tokyo Medical and Dental University Yumiko Imai, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan Tsuneyasu Kaisho, Wakayama Medical University Takanori Kanai, Keio University, Japan Hiroshi Kawamoto, Kyoto University Hisashi Arase, Osaka University, Japan Noriko Sorimachi, National Center for Global Health and Medicine Kiyoshi Takeda, Osaka University Shohei Hori, The University of Tokyo Review Talk (in Japanese) Koji Yasutomo,
  • Regulatory T Cells (Tregs): Frequently Asked Questions

    Regulatory T Cells (Tregs): Frequently Asked Questions

    BD Biosciences Technical Resources Page 1 December 2010 Regulatory T Cells (Tregs): Frequently Asked Questions What are the differences between natural Tregs and inducible Tregs? Natural Tregs (nTregs) originate from the thymus as CD4+CD25+ cells together with expression of the transcription factor FoxP3 and aren’t really influenced by the cytokine milieu. Natural Tregs represent approximately 5–10% of the total CD4+ T-cell population. They are thought to be positively selected during thymic selection, with a relatively high avidity for self-antigens. The signal to develop into Tregs is thought to come from interactions between the T-cell receptor and the complexes of MHC II with self-peptide expressed on the thymic stroma and is observed at the single-positive stage of T-lymphocyte development. On the other hand, inducible Tregs (iTregs) originate as CD4 single-positive cells from the thymus, and following adequate antigenic stimulation in the presence of cognate antigen and specialized immunoregulatory cytokines such as TGF-β, IL-10, and IL-4, differentiate into CD25+ and FoxP3+ expressing Tregs—hence called “adaptive” or “inducible” Tregs. Adaptive or inducible T cells are further categorized into Tr1, Th2, or Tr3 depending on the cytokines that modulate them.1,2 Are there any differences between mouse and human CD4+ Tregs? Yes there are. In mice, CD4+ Tregs are a homogenous population, in which all CD4+ and CD25+ cells are regulatory T cells. In humans, the Tregs are a heterogeneous population, in which not all CD25+ cells are Tregs. This was first observed by a detailed analysis of human CD4+CD25+ populations by groups at Harvard and the Royal Free and University College Medical School in London.3,4 Studies revealed that only those CD4+ cells that expressed very high levels of CD25, representing approximately 2–3% of total CD4 T cells, demonstrate the in vitro suppressive activity similar to that described in murine cells.
  • July 2020 Strategies for Emerging Infectious Diseases

    July 2020 Strategies for Emerging Infectious Diseases

    THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology.
  • An Interview with Akiko Iwasaki on Her Groundbreaking COVID Projects and Advocacy for Women and Minorities in STEM

    An Interview with Akiko Iwasaki on Her Groundbreaking COVID Projects and Advocacy for Women and Minorities in STEM

    Q&A https://doi.org/10.1038/s42003-021-02456-9 OPEN At the frontline of COVID research: an interview with Akiko Iwasaki on her groundbreaking COVID projects and advocacy for women and minorities in STEM Professor Akiko Iwasaki’s research focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. Professor Iwasaki received her Ph.D. in Immunology from the University of Toronto and completed her postdoctoral training with the National Institutes of Health before joining Yale’s faculty in 2000. She has received many awards and honors and has been a Howard Hughes Medical Institute Investigator since 2014. She was elected to the 1234567890():,; National Academy of Sciences in 2018, to the National Academy of Medicine in 2019 and to the American Academy of Arts and Sciences in 2021. Professor Iwasaki is also well known for her Twitter advocacy of women and underrepresented minorities in the science and medicine fields. In addition, Professor Iwasaki co-directs the IMPACT (Implementing Medical and Public Health Actions against Coronavirus in Connecticut) team to generate an extensive biorepository for specimens collected from patients and health care workers, as well as implementing viral testing in both groups. established. Based on this insight, we developed a vaccine strategy called “Prime and Pull”, where we can recruit and establish tissue resident memory T cells at the site of viral encounter. This led to a much more robust protection from genital herpes, and can also be used to treat existing virus infection to prevent recurrence of herpes lesions.
  • Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver

    Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver

    Confidential Page 1 of 80 Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation Version 7.0/ August 1, 2018 IND# 15479 Study Sponsor(s): The National Institute of Allergy and Infectious Diseases (NIAID) Grant #: R34AI095135 and U01AI110658-01 Study Drug Manufacturer/Provider: Sanofi US PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR SANDY FENG, MD, PHD JEFFREY BLUESTONE, PHD SANG-MO KANG, MD, FACS Professor of Surgery Executive Vice Chancellor and Provost Associate Professor Director, Abdominal Transplant A.W. Clausen Distinguished Professor University of California, San Surgery Fellowship in Medicine Francisco University of California, San University of California, San Francisco 513 Parnassus Ave. Francisco 513 Parnassus Ave. Box 0780, HSE-520 505 Parnassus Ave. Box 0400, HSW-1128 San Francisco, CA 94143-0780 Box 0780, M-896 San Francisco, CA 94143-0780 Phone: (415) 353-1888 San Francisco, CA 94143-0780 Phone: (415) 476-4451 E-mail: Sang- Phone: (415) 353-8725 Fax: (415) 476-9634 [email protected] Fax: (415) 353-8709 E-mail: [email protected] E-mail: [email protected] CO- PRINCIPAL INVESTIGATOR BIOSTATISTICIAN MEDICAL OFFICER QIZHI TANG, PHD DAVID IKLÉ, PHD NANCY BRIDGES, MD Associate Professor Senior Statistical Scientist Chief, Transplantation Branch Director, UCSF Transplantation Rho, Inc. Division of Allergy, Immunology, Research Lab 6330 Quadrangle Drive and Transplantation University of California, San Chapel Hill, NC 27517 NIAID Francisco Phone: (910) 558-6678
  • 2823.Full.Pdf

    2823.Full.Pdf

    Report on the 2018 Cancer, Autoimmunity, and Immunology Conference Colleen S. Curran, Connie L. Sommers, Howard A. Young, Katarzyna Bourcier, Marie Mancini and Elad Sharon This information is current as of September 28, 2021. J Immunol 2019; 202:2823-2828; Prepublished online 15 April 2019; doi: 10.4049/jimmunol.1900264 http://www.jimmunol.org/content/202/10/2823 Downloaded from References This article cites 15 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/202/10/2823.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Report on the 2018 Cancer, Autoimmunity, and Immunology Conference † ‡ x Colleen S. Curran,*{ Connie L. Sommers,‖ Howard A. Young, Katarzyna Bourcier, Marie Mancini, and Elad Sharon With the increased use of cancer immunotherapy, a immune-related adverse events (irAEs) that accompany cancer number of immune-related adverse events (irAEs) are immunotherapy.
  • Hangar Fire Foam Systems: a Problem in the Aviation Industry, with One Event Occuring on Average Every Six Weeks

    Hangar Fire Foam Systems: a Problem in the Aviation Industry, with One Event Occuring on Average Every Six Weeks

    PUBLICATIONS Vol.49 | No.7 $9.00 JULY 2020 | ainonline.com USAIG Accidental hangar fire foam discharge is a growing Hangar fire foam systems: a problem in the aviation industry, with one event occuring on average every six weeks. The cleanup solution looking for a problem? costs from each can involve numerous insurance by Curt Epstein claims and in some cases lawsuits, pitting aircraft For FBOs, OEMs, and other hangar keepers, senior v-p of insurance provider Global Aero- could be worth more than 10 times the price owners and operators the inadvertent discharge of fire foam sys- space and the author of a white paper on the of the building. against hangar keepers tems is a persistent and growing problem. topic, stated that the average value of foam dis- As aircraft increased in size and fuel and fire system providers. Nearly everyone has seen photos taken in charge claims he has seen has been $1 million. capacity, fire authorities began to worry the aftermath of one of these events—a NATA estimates the overall clean up and air- that sprinklers would not be able to ade- hangar filled with a thick layer of foam that craft damage costs of those events at between quately reach and fight any fuel spill fires can reach 10 feet high, spilling out on to the $64 million and $235 million. that occurred under the ever-widening ramp in some cases. The National Fire Protection Association wings, which at the time had an unpleasant Electric Aircraft In a way, accidental foam discharge is like (NFPA), considered the world’s foremost tendency to leak fuel onto the hangar floor.
  • Covid, Sex Discrimination, and Medical Research

    Covid, Sex Discrimination, and Medical Research

    COVID, SEX DISCRIMINATION, AND MEDICAL RESEARCH Lori Andrews & Bora Ndregjoni† INTRODUCTION .............................................................. 129 I. THE HISTORY OF MEDICAL RESEARCH ON WOMEN .... 131 II. THE REGULATORY ATTEMPTS TO ADDRESS THE GENDER GAP IN MEDICAL RESEARCH ................................... 135 III. THE DIFFERENTIAL EFFECT OF COVID-19 ON WOMEN AND MEN ............................................................. 143 A. Gendered Analyses of the Incidence of and Effects of COVID-19 ..................................... 145 B. Biological Differences Influencing Reactions to COVID.......................................................... 149 1. Immunological Differences ........................ 149 2. Hormonal Differences ............................... 153 3. Genetic Differences Between Men and Women ................................................................ 154 C. Emerging Studies That Use Research on Women to Guide COVID-19 Treatments.................... 156 IV. POLICY RECOMMENDATIONS .................................. 158 INTRODUCTION When I read that men are nearly twice as likely to die from COVID-19 as women,1 I thought of science fiction books that † Lori Andrews, J.D., is the Director of the Institute for Science, Law and Technology and Distinguished Professor of Law at IIT Chicago-Kent College of Law. Bora Ndregjoni is a third year law student at IIT Chicago-Kent College of Law. The authors thank Monica Pechous, Andrew White, and Kelby Roth for their research in connection with this Article. The
  • Multiscale PHATE Exploration of SARS-Cov-2 Data Reveals Multimodal Signatures of Disease

    Multiscale PHATE Exploration of SARS-Cov-2 Data Reveals Multimodal Signatures of Disease

    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.15.383661; this version posted November 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease Manik Kuchroo1∗, Jessie Huang2∗, Patrick Wong3∗, Jean-Christophe Grenier4, Dennis Shung5, Alexander Tong2, Carolina Lucas3, Jon Klein3, Daniel Burkhardt6, Scott Gigante7, Abhinav Godavarthi8, Benjamin Israelow3, Tianyang Mao3, Ji Eun Oh3, Julio Silva3, Takehiro Takahashi3, Camila D. Odio5, Arnau Casanovas-Massana9, John Fournier10, Yale IMPACT Team11, Shelli Farhadian10, Charles S. Dela Cruz12, Albert I. Ko9, F. Perry Wilson13, Julie Hussin4;14x, Guy Wolf15;16x, Akiko Iwasaki3;17x;y and Smita Krishnaswamy2;6x;y 1Department of Neuroscience, Yale University, New Haven, CT, 2Department of Computer Science, Yale University, New Haven, CT, 3Department of Immunobiology, Yale University, New Haven, CT, 4Montreal Heart Institute, Montréal, Québec, Canada, 5Department of Medicine, Yale University, New Haven, CT, 6Department of Genetics, Yale University, New Haven, CT, 7Computational Biology, Bioinformatics Program,Yale University, New Haven, CT, 8Department of Applied Mathematics, Yale University, New Haven, CT, 9Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 10Department
  • OBSERVATORIO DE LA CRISIS COVID-19 Secretaria De Investigación

    OBSERVATORIO DE LA CRISIS COVID-19 Secretaria De Investigación

    OBSERVATORIO DE LA CRISIS COVID-19 Secretaria de Investigación. Recopilación de Prensa y sitios web de interés. BOLETIN Nº15 31 de julio al 14 de agosto de 2020 INDICE Análisis estratégicos Información de Latinoamérica Argentina y México producirán la vacuna de Aumento de contagios al interior del Ejército Oxford: costará u$s 4 y estará lista en el pri- preocupa en Bolivia....................................................................27 mer semestre de 2021 .................................................................5 ONU reclama ayuda internacional a la Ama- General Juan Martín Paleo: “Vivimos la crisis zonía por avance de COVID.........................................................27 sanitaria de manera muy intensa”...............................................6 Colombia, un mes más en cuarentena......................................28 ¿Podemos volver a infectarnos del corona- virus? Los expertos creen que es muy poco Ecuador Los grupos élite de las Fuerzas Ar- probable?......................................................................................9 madas, contra el covid-19................................ ..........................29 La OMS advierte de que “quizá no haya nun- ca” una cura contra la Covid-19.................................................12 Información de América del Norte y el Caribe La OMS advierte que los efectos del Covid La Casa Blanca alerta de una expansión «ex- durarán décadas.........................................................................14 traordinaria» del Covid-19 en EE.UU.............
  • At FOCIS 2016

    At FOCIS 2016

    SAVE THE DATE Immunology by the Bay KEYNOTE SPEAKERS: Frank Nestle, MD Lewis Lanier, PhD King's College London University of California, San Francisco IMMUNOTHERAPY From Pathogens to Autoimmunity to Cancer FOCIS 2016 Supporters FOCIS gratefully acknowledges the support that allows FOCIS to fulfill its mission to foster interdisciplinary approaches to both understand and treat immune-based diseases, and ultimately to improve human health through immunology. Platinum Level Sponsors Gold Level Sponsors Silver Level Sponsors Immune Tolerance Network Bronze Level Sponsors Copper Level Sponsors Thank you to the FOCIS 2016 Travel Award Supporters: Dear Colleagues, Welcome to the 16th annual meeting of the Federation of Clinical Immunology Societies, FOCIS 2016. I am partic- ularly excited about this year’s meeting. The scientific program reflects the core tenets of FOCIS by bridging the gap between basic and clinical immunology and discussing novel translational therapies. We value the participation of each of you who have touched FOCIS in one way or another over the past 16 years, and we hope that you will join us as we move into the future. FOCIS introduced individual membership in 2012, and I invite you to join FOCIS and collaborate with us to promote education, research and patient care around the theme of translational immunology. Memberships run on a calendar year basis and are available at reasonable prices. At FOCIS 2016, membership also gains you exclusive access to a Members Only Lounge complete with a complimentary espresso bar as well as a Pushing the hip Members Only Reception in the Lighthouse on Thursday, June 23. boundaries of Please join me in extending my most heartfelt thanks to the members of the FOCIS 2016 Scientific Program Committee for their time, energy and expertise.
  • Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New- Onset Type 1 Diabetes Mellitus

    Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New- Onset Type 1 Diabetes Mellitus

    Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New- onset Type 1 Diabetes Mellitus Version:8.0 August 23, 2016 IND # 117,644 Sponsored by the Juvenile Diabetes Research Foundation International (JDRF). CONFIDENTIAL Page 1 SAFETY AND EFFICACY OF IMATINIB FOR PRESERVING BETA-CELL FUNCTION IN NEW-ONSET TYPE 1 DIABETES MELLITUS Version 7.0 ( January 29, 2016) IND # 117,644 Protocol Co-Chair Protocol Co-Chair Jeffrey A. Bluestone, Ph.D. Stephen E. Gitelman, MD Professor of Medicine, Pathology, Professor of Clinical Pediatrics Microbiology & Immunology Department of Pediatrics University of California, San Francisco University of California, San Francisco Campus Box 0540 Room S-679, Campus Box 0434 513 Parnassus Avenue 513 Parnassus Avenue San Francisco, CA 94143 San Francisco, CA 94143 Tel: 415-514-1683 Fax: 415-564-5813 Tel: 415-476-3748 Fax: 415-476-8214 Email: [email protected] Email: [email protected] This clinical study is supported by JDRF and conducted by the University of California, San Francisco. This document is confidential. It is provided for review only to investigators, potential investigators, consultants, study staff, and applicable independent ethics committees or institutional review boards. It is understood that the contents of this document will not be disclosed to others without written authorization from the study sponsor unless it is necessary to obtain informed consent from potential study participants. Imatinib in New-onset T1DM Protocol Final Version 8.0 August 23, 2016 CONFIDENTIAL Page 2 Protocol Approval Trial ID: Protocol Version: 8.0 Dated: August 23, 2016 IND # 117,644 Protocol Chairs: Jeffrey Bluestone, PhD and Stephen Gitelman, MD Title: Safety and Efficacy of Imatinib for Preserving ß-cell Function in New-onset Type 1 Diabetes Mellitus I confirm that I have read the above protocol in the latest version.